Vesicular stomatitis virus: re-inventing the bullet

Lichty, Brian D.; Power, Anthony; Stojdl, David F.; Bell, John C.

doi:10.1016/j.molmed.2004.03.003

Cited by 280 publications

(269 citation statements)

References 45 publications

Supporting

Mentioning

263

Contrasting

Unclassified

Order By: Relevance

“…VSV is exquisitely sensitive to type 1 interferon-mediated antiviral responses in untransformed cells, and consequently its selective oncotropism is attributed to the innate antiviral response suppression in tumor cells. [4][5][6][7] Although successful tumor eradication and tumor growth delay have been reported in animal models following treatment with OVs, several cancer models remain partially or completely resistant to viral oncolysis. Barriers to effective tumor oncolysis include intrinsic resistance of tumor cells to infection, limited tumor cell death induced by direct viral replication and inefficient viral spreading within the tumor mass.…”

Section: Introductionmentioning

confidence: 99%

“…13 VSV represents an excellent choice as a vector for suicide gene transduction because of selective cancer cell tropism and the relative ease of foreign gene insertion. 4,5,14 VSV engineered to express suicide enzymes allow the conversion of non-toxic prodrug into a toxic form only at the site of viral replication, thus generating specific bystander killing at the tumor site. Recombinant VSV carrying the Herpes virus TK enzyme has been shown to phosphorylate the non-toxic prodrug ganciclovir, facilitating its DNA integration and subsequent local toxicity.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy

Léveillé

Samuel

et al. 2011

Cancer Gene Ther

View full text Add to dashboard Cite

Oncolytic viruses (OVs) are promising therapeutic agents for cancer treatment, with recent studies emphasizing the combined use of chemotherapeutic compounds and prodrug suicide gene strategies to improve OV efficacy. In the present study, the synergistic activity of recombinant vesicular stomatitis virus (VSV)-MD51 virus expressing the cytosine deaminase/uracil phosphoribosyltransferase (CD::UPRT) suicide gene and 5-fluorocytosine (5FC) prodrug was investigated in triggering tumor cell oncolysis. In a panel of VSV-sensitive and -resistant cells-prostate PC3, breast MCF7 and TSA, B-lymphoma Karpas and melanoma B16-F10-the combination treatment increased killing of non-infected bystander cells in vitro via the release of 5FC toxic derivatives. In addition, we showed a synergistic effect on cancer cell killing with VSV-MD51 and the active form of the drug 5-fluorouracil. Furthermore, by monitoring VSV replication at the tumor site and maximizing 5FC bioavailability, we optimized the treatment regimen and improved survival of animals bearing TSA mammary adenocarcinoma. Altogether, this study emphasizes the potency of the VSV-CD::UPRT and 5FC combination, and demonstrates the necessity of optimizing each step of a multicomponent therapy to design efficient treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy

Léveillé

Samuel

et al. 2011

Cancer Gene Ther

View full text Add to dashboard Cite

show abstract

“…8 Viruses such as vesicular stomatitis virus often demonstrate a preference to infect and replicate in tumor cells owing to the presence of a faulty interferon response. 7,9 These studies demonstrate the potential use of viruses as an option for targeted therapy. However, not all cancer cells have a defective interferon response.…”

Section: Introductionmentioning

confidence: 85%

Fibroblast growth factor and ornithine decarboxylase 5′UTRs enable preferential expression in human prostate cancer cells and in prostate tumors of PTEN−/− transgenic mice

et al. 2011

View full text Add to dashboard Cite

In this study, we have taken advantage of over-expression of eukaryotic translation initiation factor 4E (eIF4E) in prostate cancer cells to design a viral-based targeting system of prostate cancer. Three different lengths of 5 0 -untranslated regions (5 0 UTRs) derived from either fibroblast growth factor-2 (FU-FGF2-GW) or ornithine decarboxylase (FU-ODC 149 -GW and FU-ODC 274 -GW) were inserted upstream of enhanced green fluorescent protein (GFP) gene in a lentiviral backbone. Both nonmalignant control (PNT1B and BPH-1) and neoplastic (LNCaP, C4-2, DU145 and PC-3) prostate cell lines were transfected with each plasmid or virus alone, or in the presence of siRNA against eIF4E, and their expression was monitored via GFP protein levels. Two 5 0 UTRs (FU-FGF2-GW and FU-ODC-GW) were selected as being most sensitive to eIF4E status. Lentiviruses containing these sequences were injected directly into the prostates of PTEN À/À (tumor-bearing) and control mice. Immunofluorescence data and western blot analyses determined that a lentivirus containing a 5 0 UTR derived from FGF-2 is the best candidate for directing selective gene expression in the prostate tumors of PTEN À/À mice in vivo. This study demonstrates that judicious selection of a complex 5 0 UTR can enhance selective targeting of viral-based gene therapies for prostate cancer.

show abstract

“…However, human infections are asymptomatic or at most result in a mild, transient illness. 2 VSV was among the first negative-sense RNA viruses to be generated from cloned cDNA, and its small genome and amenability to genetic manipulation make VSV conducive to use as an expression vector for foreign proteins. 3 , 4 In addition to the ability to express foreign antigens, other features of VSV contribute to its suitability as a vaccine platform.…”

Section: Introductionmentioning

confidence: 99%

The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials

Suder

Furuyama

Feldmann

et al. 2018

Human Vaccines & Immunotherapeutics

115

View full text Add to dashboard Cite

The devastating Ebola virus (EBOV) epidemic in West Africa in 2013–2016 accelerated the progress of several vaccines and antivirals through clinical trials, including the replication-competent vesicular stomatitis virus-based vaccine expressing the EBOV glycoprotein (VSV-EBOV). Extensive preclinical testing in animal models demonstrated the prophylactic and post-exposure efficacy of this vaccine, identified the mechanism of protection, and suggested it was safe for human use. Based on these data, VSV-EBOV was extensively tested in phase 1–3 clinical trials in North America, Europe and Africa. Although some side effects of vaccination were observed, these clinical trials showed that the VSV-EBOV was safe and immunogenic in humans. Moreover, the data supported the use of VSV-EBOV as an emergency vaccine in individuals at risk for Ebola virus disease. In this review, we summarize the results of the extensive preclinical and clinical testing of the VSV-EBOV vaccine.

show abstract

Vesicular stomatitis virus: re-inventing the bullet

Cited by 280 publications

References 45 publications

Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy

Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy

Fibroblast growth factor and ornithine decarboxylase 5′UTRs enable preferential expression in human prostate cancer cells and in prostate tumors of PTEN−/− transgenic mice

The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials

Contact Info

Product

Resources

About